Vancomycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Vancomycin: From Gram-Positive Bacterial Infections to Diffuse Scleroderma
One-Sentence Summary
Vancomycin is a glycopeptide antibiotic used clinically for serious Gram-positive infections (e.g. MRSA, C. difficile). The TxGNN model predicts a possible link to Diffuse Scleroderma, but this direction is currently supported by 0 clinical trials and only 1 case report, and the case report itself describes a suspected adverse drug reaction, not a therapeutic effect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Gram-positive bacterial infections (inferred from drug class; no Denmark-specific approved indication text on file) |
| Predicted New Indication | Diffuse Scleroderma |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate is not available in the evidence pack (MOA field flagged as a blocking data gap). Based on general pharmacological knowledge captured in the evidence pack’s own rationale, vancomycin acts by inhibiting D-Ala-D-Ala cell-wall synthesis in Gram-positive bacteria — a mechanism with no known relevance to diffuse scleroderma, which is an autoimmune fibrotic disease driven by fibroblast activation, TGF-β signalling, and microvascular injury.
The only supporting literature (PMID 31541072) is a 2019 case report of a patient with an exfoliative rash and eosinophilia following antibiotic therapy — this describes a suspected adverse cutaneous drug reaction, not a therapeutic benefit in scleroderma. There is no clinical trial evidence, no preclinical mechanistic study, and no established pharmacological rationale connecting an antibacterial cell-wall inhibitor to an autoimmune fibrotic disease.
Given this, the high TxGNN score most likely reflects sparse or confounded associations in the underlying knowledge graph rather than a genuine repurposing signal. The same pattern holds across the other candidates in this batch (paratyphoid fever, salmonellosis) — both are caused by Gram-negative organisms that vancomycin cannot penetrate, making those predictions mechanistically implausible as well.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31541072 | 2019 | Case Report | The American Journal of Case Reports | Describes a patient with diffuse exfoliative rash, sepsis, and eosinophilia following antibiotic treatment (including agents in the vancomycin drug class) — a suspected adverse drug reaction, not evidence of therapeutic use in scleroderma |
Denmark Market Information
Vancomycin is not currently marketed in Denmark under this evidence pack, and no marketing authorisation records are on file (0 licenses).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No drug interaction records were found in the queried database.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but there is no mechanistic rationale, no clinical trial evidence, and the single literature reference actually describes a drug-associated skin reaction rather than a treatment effect. Evidence level L5 (model prediction only) does not support advancing this candidate.
To proceed, the following is needed:
- Confirmed mechanism-of-action data for vancomycin (currently a blocking data gap, DG002)
- TFDA/SmPC warnings and contraindications (currently a blocking data gap, DG001) before any safety pre-screening (S1) can begin
- Preclinical or mechanistic studies specifically linking glycopeptide antibiotics to fibrotic/autoimmune pathways, if this candidate is to be reconsidered
- Independent re-review of the TxGNN signal, given that the top 10 ranked candidates for this drug (including paratyphoid fever and salmonellosis, both Gram-negative indications) show the same pattern of high score paired with implausible mechanism
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.